http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105476967-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86f9fd708fb86712e0772b8311214e17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2014-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0433f9d00caf75e90f8af560ea35f098 |
| publicationDate | 2016-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105476967-A |
| titleOfInvention | Blonanserin pharmaceutical composition and preparation method thereof |
| abstract | The invention discloses a blonanserin pharmaceutical composition. Mannitol and microcrystalline cellulose are used as filling agents, wherein the weight percentage of the mannitol is 40%-55%, and the weight percentage of the microcrystalline cellulose is 20%-30%. The blonanserin pharmaceutical composition is high in stability and has evident advantages of product yield increase, cost reduction, industrialization realization and clinical application, dissolubility can be effectively improved, and bioavailability is improved evidently. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108392481-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018203706-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107028903-A |
| priorityDate | 2014-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.